New Delhi, May 20 -- Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording a single-digit fall in the consolidated revenue and profit after tax (PAT).

Gland Pharma's PAT came in at Rs.187 crore for the quarter under review, as against Rs.192 crore in the year-ago quarter, recording a 3% decline on a year-on-year basis. Meanwhile, the revenue from operations declined by 7% YoY to Rs.1,425 crore in Q4 FY25, from Rs.1,538 crore in Q4 FY24.

On the operating front, the earnings before interest, tax, depreciation and amortisation (EBITDA) also fell 3% YoY to Rs.348 crore from Rs.359 crore. The EBITDA margin saw a small uptick to 24% in the March 2...